Chip-Sequencing | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Posts Tagged ‘Chip-Sequencing’

9:20AM 11/12/2014 – Panel Discussion – Genomic Technologies @10th Annual Personalized Medicine Conference at the Harvard Medical School, Boston

Posted in Academic Publishing, Conference Coverage with Social Media, Personalized and Precision Medicine & Genomic Research, Scientific & Biotech Conferences: Press Coverage, tagged #endcancer, #healtcare, #pharmaIT, #pharmanews, Agilent Technologies, Bioinformatics, Brigham and Women's, Cancer Genomics, Chip-Sequencing, clinical omics, DNA nanotechnology, emerging technologies, epigenomics, Framingham Heart Study, Full genome sequencing, genomic technology, Harvard MedicalSchool, healthcare, Illumina, MD Anderson Cancer center, personalised medicine on November 12, 2014| Leave a Comment »

9:20AM 11/12/2014 – 10th Annual Personalized Medicine Conference at the Harvard Medical School, Boston

Reporter: Aviva Lev-Ari, PhD, RN

REAL TIME Coverage of this Conference by Dr. Aviva Lev-Ari, PhD, RN – Director and Founder of LEADERS in PHARMACEUTICAL BUSINESS INTELLIGENCE, Boston http://pharmaceuticalintelligence.com

9:20 a.m. Panel Discussion – Genomic Technologies

Genomic Technologies

The greatest impetus for personalized medicine is the initial sequencing of the human genome at the beginning of this Century. As we began to recognize the importance of genetic factors in human health and disease, efforts to understand genetic variation and its impact on health have accelerated. It was estimated that it cost more than two billion dollars to sequence the first human genome and reduction in the cost of sequence became an imperative to apply this technology to many facets of risk assessment, diagnosis, prognosis and therapeutic intervention. This panel will take a brief historical look back at how the technologies have evolved over the last 15 years and what the future holds and how these technologies are being applied to patient care.

Genomic Technologies

Opening Speaker and Moderator:

George Church, Ph.D.
Professor of Genetics, Harvard Medical School; Director, Personal Genomics

Genomic Technologies and Sequencing

highly predictive, preventative
non predictive

Shareable Human Genomes Omics Standards

$800 Human Genome Sequence – Moore’s Law does not account for the rapid decrease in cost of Genome Sequencing

Genome Technologies and Applications

Genia nanopore – battery operated device
RNA & protein traffic
Molecular Stratification Methods – more than one read, sequence ties
Brain Atlas – transcriptome of mouse brains
Multigenics – 700 genes: hGH therapies

Therapies

vaccine
hygiene
age

~1970 Gene Therapy in Clinical Trials

Is Omic technologies — a Commodity?

Some practices will have protocols
other will never become a commodity

Panelists:

Sam Hanash, M.D., Ph.D. @MDAndersonNews

Director, Red & Charline McCombs Institute for Early Detection & Treatment of Cancer MD Anderson Cancer Center

Heterogeneity among Cancer cells. Data analysis and interpretation is very difficult, back up technology

Proteins and Peptides before analysis with spectrometry:

PM – Immunotherapy approaches need be combined with other techniques
How modification in protein type affects disease
amplification of an aberrant protein – when that happens cancer developed. Modeling on a CHip of peptide synthesizer

Mark Stevenson @servingscience

Executive Vice President and President, Life Sciences Solutions
Thermo Fisher Scientific

Issues of a Diagnostics Developer:

FDA regulation, need to test on several tissues
computational environment
PCR, qPCR – cost effective
BGI – competitiveness

Robert Green, MD @BrighamWomens

Partners, Health Care Personalized Medicine — >>Disclosure: Illumina and three Pharmas

Innovative Clinical Trial: Alzheimer’s Disease, integration of sequencing with drug development

Population based screening with diagnosis
Cancer predisposition: Cost, Value, BRCA
epigenomics technologies to be integrated
Real-time diagnostics
Screening makes assumption on Predisposition
Public Health view: Phenotypes in the Framingham Studies: 64% pathogenic genes were prevalent – complication based in sequencing.

Questions from the Podium:

Variants analysis
Metastasis different than solid tumor itself – Genomics will not answer issues related to tumor in special tissues variability

– See more at: http://personalizedmedicine.partners.org/Education/Personalized-Medicine-Conference/Program.aspx#sthash.qGbGZXXf.dpuf

Acute Myeloid Leukemia (AML): Role of Chromatin Accessibility during Hematopoiesis

Posted in Bio Instrumentation in Experimental Life Sciences Research, Biological Networks, Gene Regulation and Evolution, Biomarkers & Medical Diagnostics, CANCER BIOLOGY & Innovations in Cancer Therapy, Computational Biology/Systems and Bioinformatics, Genome Biology, Genomic Testing: Methodology for Diagnosis, Molecular Genetics & Pharmaceutical, Personalized and Precision Medicine & Genomic Research, Population Health Management, Genetics & Pharmaceutical, Statistical Methods for Research Evaluation, Technology Transfer: Biotech and Pharmaceutical, tagged Binding site, Biochemistry and Molecular Biology, Chip-Sequencing, DNA, gene expression, Histone, Nijmegen on August 31, 2012| 1 Comment »

Reporter: Aviva Lev-Ari, PhD, RN

Blood. 2012 Aug 24. [Epub ahead of print]

Chromatin accessibility, p300 and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia.

Saeed S, Logie C, Francoijs KJ, Frigè G, Romanenghi M, Nielsen FG, Raats L, Shahhoseini M, Huynen M, Altucci L, Minucci S, Martens JH, Stunnenberg HG.

Source

Radboud University, Department of Molecular Biology, Faculty of Science, Nijmegen Centre for Molecular Life Sciences, Nijmegen, Netherlands;

Abstract

Chromatin accessibility plays a key role in regulating cell type specific gene expression during hematopoiesis, but has also been suggested to be aberrantly regulated during leukemogenesis. To understand the leukemogenic chromatin signature we analyzed acute promyelocytic leukemia (APL), a subtype of leukemia characterized by the expression of RARα-fusion proteins such as PML-RARα. We used nuclease accessibility sequencing in cell lines as well as patient blasts to identify accessible DNA elements and identified over 100,000 accessible regions in each case. Using ChIP-seq we identified H2A.Z as a histone modification generally associated with these accessible regions while unsupervised clustering analysis of other chromatin features including DNA methylation, H2A.Zac, H3ac, H3K9me3, H3K27me3 and the regulatory factor p300 distinguished six distinct clusters of accessible sites, each with a characteristic functional make-up. Of these, PML-RARα binding was found specifically at accessible chromatin regions characterized by p300 binding and hypoacetylated histones. Identifying regions with a similar epigenetic make up in t(8;21) AML cells, another subtype of AMLs, revealed that these regions are occupied by the oncofusion protein AML1-ETO. Together our results suggest that oncofusion proteins localize to accessible regions and that chromatin accessibility together with p300 binding and histone acetylation characterize AML1-ETO and PML-RARα binding sites.